Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Coherex WAVECREST I Left Atrial Appendage Occlusion Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02239887
Recruitment Status : Completed
First Posted : September 15, 2014
Last Update Posted : January 15, 2015
Sponsor:
Information provided by (Responsible Party):
Coherex Medical

Tracking Information
First Submitted Date September 11, 2014
First Posted Date September 15, 2014
Last Update Posted Date January 15, 2015
Study Start Date October 2010
Actual Primary Completion Date November 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 12, 2014)
  • Primary Safety Endpoint [ Time Frame: 45 Days post procedure ]
    The primary safety endpoint is the incidence of major adverse events up to 45 days post-procedure. Major adverse events are defined as life-threatening incidents as determined by the Clinical Events Committee (CEC) and include events such as device embolization; cardiac injury, re-intervention, and/or device-related surgery; bleeding events such as pericardial effusion requiring drainage, cranial bleeding due to any source, gastrointestinal bleeding; or any other event related to the device or the procedure, which requires treatment.
  • Primary Efficacy Endpoint [ Time Frame: 45 and/or 180 days post procedure ]
    The primary efficacy endpoint is the incidence of LAA occlusion at 45 and/or 180 days (+ten days) post-procedure. LAA occlusion will be assessed by transesophageal echocardiography (TEE) color flow Doppler and will be defined as absence of flow in the LAA or color flow Doppler jets less than 3mm.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: September 12, 2014)
  • Secondary Safety Endpoint [ Time Frame: 180 days and one year post-procedure ]
    The secondary safety endpoint is the incidence of serious adverse events at 180 days and one year post-procedure. Serious adverse events are defined as any events that result in death, are life-threatening, require in-patient hospitalization or prolongation of existing hospitalization, or result in permanent or significant disability/incapacity.
  • Secondary Efficacy Endpoints [ Time Frame: intra operative ]
    1. Procedural success, defined as successful delivery, deployment, and release of the Coherex WaveCrest Left Atrial Appendage Occlusion System into the LAA, and includes successful recapture and retrieval, if necessary.
    2. The incidence of LAA occlusion as measured by echocardiographic color flow Doppler jets less than 3mm by TEE at the end of the procedure.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Coherex WAVECREST I Left Atrial Appendage Occlusion Study
Official Title Coherex WAVECREST I Left Atrial Appendage Occlusion Study
Brief Summary Purpose To establish the safety and efficacy of the Coherex WaveCrest Left Atrial Appendage Occlusion System for left atrial appendage (LAA) closure during treatment of non-valvular atrial fibrillation in patients who are at increased risk for embolic stroke and have an ongoing indication for oral anticoagulation.
Detailed Description

Primary Safety Endpoint The primary safety endpoint is the incidence of major adverse events up to 45 days post-procedure. Major adverse events are defined as life-threatening incidents as determined by the Clinical Events Committee (CEC) and include events such as device embolization; cardiac injury, re-intervention, and/or device-related surgery; bleeding events such as pericardial effusion requiring drainage, cranial bleeding due to any source, gastrointestinal bleeding; or any other event related to the device or the procedure, which requires treatment.

Primary Efficacy Endpoint The primary efficacy endpoint is the incidence of LAA occlusion at 45 and/or 180 days (+ten days) post-procedure. LAA occlusion will be assessed by transesophageal echocardiography (TEE) color flow Doppler and will be defined as absence of flow in the LAA or color flow Doppler jets less than 3mm.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population The target population for this study is the subset of patients who have non-valvular paroxysmal, persistent, or permanent atrial fibrillation; LAA anatomy amenable to treatment by percutaneous techniques; and an anticoagulation indication for potential thrombus formation in the left atrium. Patients with an absolute or relative contraindication to anticoagulants will also be included.
Condition
  • Non-valvular Paroxysmal, Persistent, or Permanent Atrial Fibrillation
  • LAA Anatomy Amenable to Treatment by Percutaneous Technique
  • Anticoagulation Indication for Potential Thrombus Formation in the Left Atrium
Intervention Device: WaveCrest LAA occlusion device
Left Atrial Appendage Occlusion
Study Groups/Cohorts WaveCrest LAA occlusion device
Left Atrial Occlusion
Intervention: Device: WaveCrest LAA occlusion device
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 12, 2014)
155
Original Actual Enrollment Same as current
Actual Study Completion Date November 2014
Actual Primary Completion Date November 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:Candidates for this study must meet ALL of the following criteria

  1. At least 18 years of age.
  2. Diagnosis of paroxysmal, persistent, or permanent non-valvular atrial fibrillation.
  3. Indicated for long-term anticoagulation therapy including patients on anticoagulants and patients with a contraindication to anticoagulation. The first 30 patients must have a contraindication to anticoagulation.
  4. Eligible for cessation of anticoagulation therapy if the LAA is sealed (i.e., the patient has no other condition requiring anticoagulation therapy).
  5. Calculated CHADS score ≥ 1.
  6. Willingness to participate in the required follow-up visits and tests.
  7. Willingness of patient or legal representative to provide written informed consent.
  8. Female subjects of child-bearing potential must have a negative serum pregnancy test within 7 days prior to the index procedure, and must be willing to use reliable contraception methods for one year post-procedure.

Exclusion Criteria:

  1. Known contraindication and/or allergy to aspirin, clopidogrel, IV contrast, or nickel.
  2. Extensive congenital cardiac anomalies, which can only be adequately repaired by cardiac surgery.
  3. Stroke or transient ischemic attack (TIA), as diagnosed by a neurologist, within the past 30 days. Patients with a history of stroke or TIA will not be allowed to enroll until 30 days post stroke or TIA have been completed.
  4. New York Heart Association Class IV Congestive Heart Failure, defined as patients with severe physical limitations and symptoms even while at rest.
  5. Myocardial infarction within the past three months.
  6. Sepsis within one month prior to implantation or any systemic infection that cannot be successfully treated prior to device placement.
  7. Presence of an atrial septal defect, atrial septal repair, or atrial septal closure device.
  8. Female subjects who may be pregnant or are planning on becoming pregnant in the next year.
  9. Cardioversion or ablation procedure planned in conjunction with or within 30 days after placement of the Coherex WaveCrest Left Atrial Appendage Occlusion System.
  10. Cardiac transplant or mechanical valve.
  11. Symptomatic carotid artery disease.
  12. Any medical disorder or psychiatric illness that would interfere with successful completion of the study as determined by the investigator.
  13. Conditions other than atrial fibrillation requiring long-term warfarin therapy.
  14. Resting heart rate > 110 beats per minute (bpm).
  15. A single episode of transient atrial fibrillation.
  16. Thrombocytopenia (<50,000 platelets/mm3), thrombocythemia (>700,000 platelets/mm³), leucopenia (white blood cell count < 3,000 cells/mm³), or anemia (hemoglobin concentration < 10 gram per deciliter [g/dl]).
  17. Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints. (Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.)
  18. Any condition that would reduce life expectancy to less than two years from the date of the index procedure.

Echocardiographic criteria for exclusion:

  1. Left ventricular ejection fraction (LVEF) < 30%.
  2. Mitral valve stenosis < 1.5 cm2 or any stenosis consistent with rheumatic valvular disease.
  3. Pericardial effusion > 5 mm pre-procedure.
  4. Evidence of intracardiac thrombus visualized on TEE.
  5. Presence of a patent foramen ovale (PFO) that demonstrates a large shunt and/or atrial septal aneurysm with > 10 mm excursion.
  6. Cardiac tumor.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT02239887
Other Study ID Numbers IP005
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Coherex Medical
Study Sponsor Coherex Medical
Collaborators Not Provided
Investigators Not Provided
PRS Account Coherex Medical
Verification Date January 2015